Cargando…
2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D(1) Receptor for Parkinson’s Disease
[Image: see text] Tolerance development caused by dopamine replacement with l-DOPA and therapeutic drawbacks upon activation of dopaminergic receptors with orthosteric agonists reveal a significant unmet need for safe and effective treatment of Parkinson’s disease. In search for selective modulators...
Autores principales: | García-Cárceles, Javier, Vázquez-Villa, Henar, Brea, José, Ladron de Guevara-Miranda, David, Cincilla, Giovanni, Sánchez-Martínez, Melchor, Sánchez-Merino, Anabel, Algar, Sergio, Teresa de los Frailes, María, Roberts, Richard S., Ballesteros, Juan A., Rodríguez de Fonseca, Fernando, Benhamú, Bellinda, Loza, María I., López-Rodríguez, María L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511493/ https://www.ncbi.nlm.nih.gov/pubmed/36044544 http://dx.doi.org/10.1021/acs.jmedchem.2c00949 |
Ejemplares similares
-
Novel Antagonist
of the Type 2 Lysophosphatidic Acid
Receptor (LPA(2)), UCM-14216, Ameliorates Spinal Cord Injury
in Mice
por: Khiar-Fernández, Nora, et al.
Publicado: (2022) -
New Trends in Aging Drug Discovery
por: Benhamú, Bellinda, et al.
Publicado: (2022) -
Discovery of V-0219:
A Small-Molecule Positive
Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor
toward Oral Treatment for “Diabesity”
por: Decara, Juan M., et al.
Publicado: (2022) -
A new serotonin 5-HT(6) receptor antagonist with procognitive activity – Importance of a halogen bond interaction to stabilize the binding
por: González-Vera, Juan A., et al.
Publicado: (2017) -
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
por: Martínez, Antón L., et al.
Publicado: (2021)